What is Gilead Sciences's less than 12 months?

Gilead Sciences (GILD) reported less than 12 months of $669.00M in Q1 2026.

What is the long-term trend for Gilead Sciences's less than 12 months?

Over 2 years (2022 to 2025), Gilead Sciences's less than 12 months has grown at a -22.5% compound annual growth rate (CAGR), from $1.20B to $724.00M.

Other

Less than 12 months

Gilead Sciences Less than 12 months decreased by 7.6% to $669.00M in Q1 2026 compared to the prior quarter. Over 2 years (FY 2022 to FY 2025), Less than 12 months shows a downward trend with a -22.5% CAGR.

Analysis

StatementBalance Sheet Statement

SectionOther

First reportedQ4 2017

Last reportedQ1 2026May 7, 2026

Metric ID: other_debt_securities_available_for_sale_continuous_unre_4cdf47

Historical Data

8 periods

	Q4 '22	Q1 '23	Q2 '23	Q3 '23	Q4 '23	Q2 '25	Q4 '25	Q1 '26
Value	$1.20B	$862.00M	$1.25B	$1.24B	$727.00M	$519.00M	$724.00M	$669.00M
QoQ Change	—	-28.4%	+44.5%	-0.6%	-41.3%	-28.6%	+39.5%	-7.6%
YoY Change	—	—	—	—	-39.6%	—	—	—

Range$519.00M – $1.25B

CAGR-28.5%

Avg YoY Growth-39.6%

Median YoY Growth-39.6%

Frequently Asked Questions

What is Gilead Sciences's less than 12 months?: Gilead Sciences (GILD) reported less than 12 months of $669.00M in Q1 2026.
What is the long-term trend for Gilead Sciences's less than 12 months?: Over 2 years (2022 to 2025), Gilead Sciences's less than 12 months has grown at a -22.5% compound annual growth rate (CAGR), from $1.20B to $724.00M.